Master ADC Manufacturing Compliance with Wisdom's Expert Training
Training Schedule (2 December, 2024)
10:00 - 15:00 PM US EST time
Online
Join visionary speakers from leading organisations for crucial insights and expert opinions.
Rakesh Dixit,
Rakesh Dixit is an accomplished executive, inventor, and scientist with over 35 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, and MedImmune - AstraZeneca. He is President and CSO of Regio Biosciences and Bionavigen Oncology, LLC. From 2006 to 2019, Rakesh was a Global Vice President of the Biologics R&D at MedImmune - AstraZeneca. He is a Board Member of Regio Biosciences and a key member of multiple scientific advisory boards. Rakesh is also a chief adviser and consultant for over 20 companies worldwide. His biopharmaceutical peers selected Rakesh as one of the 100 Most Inspiring People in the Pharmaceutical Industry by PharmaVOICE in 2015. Rakesh received the Most Prestigious Award of Long-Standing Contribution to ADCs by World ADC (Hanson-Wade), 2020. From 2006 to 2019, Rakesh was a Global Vice President of the Biologics R&D at MedImmune - AstraZeneca.
Training Schedule (2 December, 2024)
10:00 - 15:00 PM US EST
Antibody-drug conjugates (ADCs), also known as magic bullets for cancer, are the most rapidly advancing therapeutics in treating cancers. There is an increasing appreciation of the high potential of ADCs for autoimmune diseases. However, unlike small molecule drug or antibody therapeutics, ADCs are complex molecules consisting of three components:
(1) The targeting antibody with high affinity for tumor-specific or dominant antigen
(2) The anticancer payload, typically a very potent cytotoxic drug
(3) The cleavable/uncleavable linker connecting the payload to antibody.
Although 13 ADCs are approved for treating cancers, an increasing number of ADCs are also being terminated in clinical development due to poor efficacy, limited durability of response, and, most importantly, unacceptable toxicities.. The training course will discuss intelligent strategies for creating best-in-class ADCs, including target choice, linker selection, conjugation methods, and preclinical /clinical efficacy evaluation.
Quality
Quality assurance
Quality Control
CMC Managers/ Heads
Compliance
Regulatory Affairs
QA/QC Managers
Analytical Scientists
Development Scientists
Manufacturing
Process Development
Upstream/Downstream
R&D Scientists
Operations
& VC/investors in Biologics
Directors
Sr. Directors
VP
SVO
CEO
CSO
CDO
Senior and Principal Scientists
Draft Schedule:
10:00-11:00 Introduction to Antibody-based ADCs in cancer and non-cancer indication
11:00-12:00 Challenges to attaining acceptable therapeutic index of ADCs
Join visionary speakers from leading organisations for crucial insights and expert opinions.
We are a high-profile corporate events organiser for professionals from commercial, government, and research segments. We deliver summits, conferences, exhibitions, and business meetings of exceptional quality, encompassing diverse industry verticals such as pharma, energy, maritime, agro, technology, healthcare, marketing, and more.
Visit our website: wisdom.events
